Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877991 | 0.88 | CYSLTR1 (0.52) | CYSLTR1CYSLTR2CYP1A2PDE10APSMB5 | |
| SCHEMBL7085590 | 0.81 | CYSLTR1 (0.49) | CYSLTR1CYSLTR2CYP1A2PDE10ACYP2E1 | |
| SCHEMBL9867265 | 0.79 | PSMB5 (0.44) | CYSLTR1CYSLTR2CYP1A2PDE10APSMB5 | |
| SCHEMBL267839 | 0.78 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL23844622 | 0.77 | CYP1A2 (0.52) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL11180126 | 0.76 | CYSLTR1 (0.45) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL3704591 | 0.76 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL177540 | 0.75 | PDE10A (0.50) | CYSLTR1CYSLTR2CYP1A2PDE10ACYP3A4 | |
| SCHEMBL10546745 | 0.74 | CYSLTR2 (0.50) | CYSLTR1CYSLTR2CYP1A2PDE10ARAB9A | |
| SCHEMBL3267444 | 0.73 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2CYP1A2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220770-B2 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2007-05-22 | — | — | US | claimed |
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2005-11-17 | — | — | US | claimed |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2005-05-05 | — | — | US | claimed |
| US-6613789-B2 | Especially for treating arthritis, pain and fever | G. D. SEARLE & CO. | 2003-09-02 | — | — | US | claimed |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2003-02-20 | — | — | US | claimed |
| EP-0880504-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | claimed |
| WO-1997027181-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-07-31 | — | — | WO | claimed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | claimed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | claimed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | claimed |
| US-7220770-B2 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2007-05-22 | — | — | US | disclosed |
| EP-1193265-B1 | A process for the preparation of 4-¬2-(aryl or heterocyclo)-1H-imidazol-1-yl|benzenesulfonamides | SEARLE LLC (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | KHANNA ISH K | 2005-11-17 | — | — | US | disclosed |
| US-6960611-B2 | Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof | INSTITUTE OF MATERIA MEDICA (CN) | 2005-11-01 | — | — | US | disclosed |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2005-05-05 | — | — | US | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5620999-A | ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT | G.D. SEARLE & CO. | 1997-04-15 | — | — | US | disclosed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256120-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | LTC4S, HRH4, LTB4R2 | CYSLTR1 8/4885CYSLTR2 6/4885CYP1A2 921/4885 |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HCK, IL4I1, AHR | CYSLTR1 10/4885CYSLTR2 6/4885CYP1A2 1041/4885 |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HRH4, LTC4S, HCAR3 | CYSLTR1 14/4885CYSLTR2 9/4885CYP1A2 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.